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Genome-Wide
Epigenetic and
Transcriptomic
Characterization of
Human-Induced
Pluripotent Stem
Cell–Derived Intestinal
Epithelial OrganoidsHuman induced pluripotent stem cells
(iPSC) have been used to generate
intestinal organoids that mimic key
intestinal properties without the
requirement for invasive procedures
to obtain human tissues. The main
protocols that have been described
result in gut organoids that contain
both intestinal epithelium as well as
mesenchymal cells.1,2 We have previ-
ously reported on human iPSC-derived
intestinal organoids (iPSCo) that can
be propagated in long-term culture
that contain solely epithelial cells.3–7 A
pure epithelial model offers unique
opportunities to study epithelial cell
intrinsic and cell-type–speciﬁc mecha-
nisms. Among these cellular processes
are epigenetic mechanisms such as
DNA methylation, which acts as a key
regulator of intestinal epithelial devel-
opment and regional identity.1,7 The
purpose of this study was to charac-
terize iPSCo by comparing these
cultures with primary puriﬁed intesti-
nal epithelial cells (IECs).
Intestinal epithelial organoid cul-
tures were derived from at least 3
different lines of iPSCs according to
the described protocol3–5 (see also
Supplementary Figure 1), and showed
a morphology comparable with
mucosal biopsy-derived intestinal
epithelial organoids. This was high-
lighted by the presence of epithelial
cell adhesion molecules and epithelial
polarization (Figure 1A). Further-
more, iPSCos were found to express
several epithelial cell markers
including E-cadherin (CDH1) and the
intestinal stem cell marker LGR5
(Figure 1B). Immunoﬂuorescent
staining showed ubiquitous positivityfor the enterocyte marker villin, with
speciﬁc subsets of cells expressing
mucin 2, chromogranin A, and lyso-
zyme, markers associated with the
epithelial cell subsets Goblet, enter-
oendocrine, and Paneth cells, respec-
tively (Figure 1B and C).
To further evaluate regional iden-
tity and the degree of developmental
maturation of iPSCos, we performed
DNA methylation and transcriptomic
proﬁling using Illumina (Illumina,
Cambridge, UK) Inﬁnium bead arrays
and RNA sequencing, respectively.
We compared these genome-wide
proﬁles with data sets we previously
derived from puriﬁed IECs from
mature terminal ileum and sigmoid
colon (SC), as well as human fetal
proximal gut and fetal distal gut
(Supplementary Tables 1 and 2).6
Relative sample similarity based on
multidimensional scaling indicated
that iPSCos clustered more closely to
mature colonic epithelium, both on an
epigenetic (ie, DNA methylation) and
transcriptomic level (Figure 2A and B).
This was conﬁrmed further by per-
forming unsupervised, hierarchical
clustering (Supplementary Figure 2),
as well as differential DNA methyl-
ation and gene expression analyses.
The latter showed that iPSCos had a
greater number of signiﬁcantly
differentially methylated positions
(adjusted P < .01) and differentially
expressed genes (adjusted P < .01) in
common with the SC than with
the terminal ileum (Figure 2C,
Supplementary Table 3).
Given the overall similarity with
pediatric sigmoid colon epithelium,
we examined this relationship in more
detail using mucosa-derived SC orga-
noids (SCos) as an additional refer-
ence (Supplementary Figure 3A and
B). We focused on the most signiﬁcant
differentially expressed genes
(adjusted P < .01) between iPSCo and
either puriﬁed IECs (SC puriﬁed
epithelium) or organoids (SCo),
respectively. Interestingly, some key
small intestinal markers for Paneth
cells (eg, a-defensins DEFA5 and
DEFA6) were abundant in iPSCo, while
several genes involved in innatedefense (eg, IFI27, HCP5, PIGR)
showed markedly lower expression
levels (Figure 2D). This indicated that
iPSCos may not reach the full level of
differentiation into small or large in-
testinal epithelium as found in vivo.
Thus, iPSCo models may require
further optimization of the differenti-
ation protocol to permit further
maturation and regionalization.
Studying the signaling pathways that
could drive this maturation could
offer unique insight into the processes
involved in intestinal development.
Together, our ﬁndings indicate that
iPSC-derived human intestinal epithe-
lial cell organoids more closely
resemble mature colonic epithelium,
which is in keeping with reports from
other groups using alternative pro-
tocols to achieve distalization and
maturation.8–10 However, using a
genome-wide approach to validate the
iPSCo model also uncovered distinct
differences and incomplete regionali-
zation of iPSC-derived organoids
compared with human primary cells.
These observations provide an ideal
starting point to further investigate the
factors required to model complete
epithelial development in vitro.
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Figure 1. Characterization of iPSC-derived intestinal epithelial organoids. (A) Intestinal epithelial organoids derived from
PSCs (iPSCo), terminal ileum organoids (TIo), or SC organoids (SCo) in microscopic brightﬁeld view (upper panel), or
immunoﬂuorescent staining for epithelial cell adhesion molecule (epithelial cell adhesion molecule [EpCAM], green), actin (red),
and nuclei (blue). Scale bars: 400 mm. (B) Expression of IEC-type marker as normalized counts from RNA sequencing data of
the respective organoids. Bar shows means ± SD, n ¼ 4–5 per group. (C) Immunoﬂuorescent staining for enterocyte marker
villin (VIL1, green), goblet cell marker mucin 2 (MUC2, green), enteroendocrine marker chromogranin A (CHGA, green), Paneth
cell marker lysozyme (LYZ, red), and nuclear counterstain (blue), Scale bars: 100 um.
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Figure 2. Genome-wide proﬁling of human iPSCo and puriﬁed IECs. (A) Multidimensional scaling plot showing sample
similarity of genome-wide DNA methylation measured by an Illumina 450K array of iPSCo, in the context of IECs derived from
terminal ileum (TI), SC, fetal proximal gut (FGP), and fetal distal gut (FDG).1 Each symbol represents a sample, x ¼ IEC, o ¼
organoid. (B) MDS plot of RNA-sequencing proﬁles showing the same sample groups as in panel A. Sample distance in the
plot is based on regularized-logarithmic transformed read counts of all expressed genes. (C) Venn diagram indicating the
number of differentially methylated CpG positions (top) or differentially expressed genes (bottom) (adjusted P < .01) between
the different groups. (D) Heatmap of expression values (regularized-logarithmic normalized counts) of the top 20 most
signiﬁcantly differentially expressed genes comparing iPSCo and SC puriﬁed epithelium (SCp) (left), and iPSCo and SCo (right)
for all 3 sample groups. The scale indicates the row mean Z-score (means, 0). The dendrogram above the heatmap clusters
samples based on the expression similarity of those genes.
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